Selected research
Industry Research
Vulvar and Vaginal Atrophy Therapy Industry Research Report 2026
Market perspective
The global Vulvar and Vaginal Atrophy Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vulvar and Vaginal Atrophy Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vulvar and Vaginal Atrophy Therapy is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vulvar and Vaginal Atrophy Therapy is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vulvar and Vaginal Atrophy Therapy include Viveve, VenusConcept, ThermiGen LLC, Lutronic, Hologic, Fotona, BTL Group of Companies, Almirall and Alma Lasers, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vulvar and Vaginal Atrophy Therapy market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vulvar and Vaginal Atrophy Therapy Market by Company
Viveve
VenusConcept
ThermiGen LLC
Lutronic
Hologic
Fotona
BTL Group of Companies
Almirall
Alma Lasers
Vulvar and Vaginal Atrophy Therapy Segment by Type
Vulvar Atrophy Therapy
Vaginal Atrophy Therapy
Vulvar and Vaginal Atrophy Therapy Segment by Application
Specialty Clinics
Hospitals
Ambulatory Surgical Centers
Others
Vulvar and Vaginal Atrophy Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vulvar and Vaginal Atrophy Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vulvar and Vaginal Atrophy Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vulvar and Vaginal Atrophy Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vulvar and Vaginal Atrophy Therapy manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vulvar and Vaginal Atrophy Therapy by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vulvar and Vaginal Atrophy Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Vulvar Atrophy Therapy
- Vaginal Atrophy Therapy
Applications
- Specialty Clinics
- Hospitals
- Ambulatory Surgical Centers
- Others
Companies covered
- Viveve
- VenusConcept
- ThermiGen LLC
- Lutronic
- Hologic
- Fotona
- BTL Group of Companies
- Almirall
- Alma Lasers
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vulvar and Vaginal Atrophy Therapy Market Size (2021-2032)
- 2.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales (2021-2032)
- 2.2.3 Global Vulvar and Vaginal Atrophy Therapy Market Average Price (2021-2032)
- 2.3 Vulvar and Vaginal Atrophy Therapy by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Vulvar Atrophy Therapy
- 2.3.3 Vaginal Atrophy Therapy
- 2.4 Vulvar and Vaginal Atrophy Therapy by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Specialty Clinics
- 2.4.3 Hospitals
- 2.4.4 Ambulatory Surgical Centers
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vulvar and Vaginal Atrophy Therapy Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vulvar and Vaginal Atrophy Therapy Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Vulvar and Vaginal Atrophy Therapy Revenue of Manufacturers (2021-2026)
- 3.4 Global Vulvar and Vaginal Atrophy Therapy Average Price by Manufacturers (2021-2026)
- 3.5 Global Vulvar and Vaginal Atrophy Therapy Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vulvar and Vaginal Atrophy Therapy, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vulvar and Vaginal Atrophy Therapy, Product Type & Application
- 3.8 Global Manufacturers of Vulvar and Vaginal Atrophy Therapy, Established Date
- 3.9 Global Vulvar and Vaginal Atrophy Therapy Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Viveve
- 4.1.1 Viveve Company Information
- 4.1.2 Viveve Business Overview
- 4.1.3 Viveve Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Viveve Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.1.5 Viveve Recent Developments
- 4.2 VenusConcept
- 4.2.1 VenusConcept Company Information
- 4.2.2 VenusConcept Business Overview
- 4.2.3 VenusConcept Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 VenusConcept Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.2.5 VenusConcept Recent Developments
- 4.3 ThermiGen LLC
- 4.3.1 ThermiGen LLC Company Information
- 4.3.2 ThermiGen LLC Business Overview
- 4.3.3 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 ThermiGen LLC Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.3.5 ThermiGen LLC Recent Developments
- 4.4 Lutronic
- 4.4.1 Lutronic Company Information
- 4.4.2 Lutronic Business Overview
- 4.4.3 Lutronic Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Lutronic Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.4.5 Lutronic Recent Developments
- 4.5 Hologic
- 4.5.1 Hologic Company Information
- 4.5.2 Hologic Business Overview
- 4.5.3 Hologic Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hologic Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.5.5 Hologic Recent Developments
- 4.6 Fotona
- 4.6.1 Fotona Company Information
- 4.6.2 Fotona Business Overview
- 4.6.3 Fotona Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Fotona Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.6.5 Fotona Recent Developments
- 4.7 BTL Group of Companies
- 4.7.1 BTL Group of Companies Company Information
- 4.7.2 BTL Group of Companies Business Overview
- 4.7.3 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 BTL Group of Companies Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.7.5 BTL Group of Companies Recent Developments
- 4.8 Almirall
- 4.8.1 Almirall Company Information
- 4.8.2 Almirall Business Overview
- 4.8.3 Almirall Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Almirall Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.8.5 Almirall Recent Developments
- 4.9 Alma Lasers
- 4.9.1 Alma Lasers Company Information
- 4.9.2 Alma Lasers Business Overview
- 4.9.3 Alma Lasers Vulvar and Vaginal Atrophy Therapy Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Alma Lasers Vulvar and Vaginal Atrophy Therapy Product Portfolio
- 4.9.5 Alma Lasers Recent Developments
5 Global Vulvar and Vaginal Atrophy Therapy Market Scenario by Region
- 5.1 Global Vulvar and Vaginal Atrophy Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021-2032
- 5.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2021-2026
- 5.2.2 Global Vulvar and Vaginal Atrophy Therapy Sales by Region: 2027-2032
- 5.3 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region: 2021-2032
- 5.3.1 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region: 2021-2026
- 5.3.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Region: 2027-2032
- 5.4 North America Vulvar and Vaginal Atrophy Therapy Market Facts & Figures by Country
- 5.4.1 North America Vulvar and Vaginal Atrophy Therapy Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
- 5.4.3 North America Vulvar and Vaginal Atrophy Therapy Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Vulvar and Vaginal Atrophy Therapy Market Facts & Figures by Country
- 5.5.1 Europe Vulvar and Vaginal Atrophy Therapy Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
- 5.5.3 Europe Vulvar and Vaginal Atrophy Therapy Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.5.9 Nordic Countries
- 5.6 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vulvar and Vaginal Atrophy Therapy Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vulvar and Vaginal Atrophy Therapy Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vulvar and Vaginal Atrophy Therapy Market Facts & Figures by Country
- 5.7.1 South America Vulvar and Vaginal Atrophy Therapy Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
- 5.7.3 South America Vulvar and Vaginal Atrophy Therapy Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Vulvar and Vaginal Atrophy Therapy Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vulvar and Vaginal Atrophy Therapy Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vulvar and Vaginal Atrophy Therapy Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vulvar and Vaginal Atrophy Therapy Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032)
- 6.1.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Type (2021-2032)
- 6.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Type (2021-2032)
- 6.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Type (2021-2032)
- 6.3 Global Vulvar and Vaginal Atrophy Therapy Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032)
- 7.1.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Vulvar and Vaginal Atrophy Therapy Sales Market Share by Application (2021-2032)
- 7.2 Global Vulvar and Vaginal Atrophy Therapy Revenue by Application (2021-2032)
- 7.2.1 Global Vulvar and Vaginal Atrophy Therapy Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vulvar and Vaginal Atrophy Therapy Revenue Market Share by Application (2021-2032)
- 7.3 Global Vulvar and Vaginal Atrophy Therapy Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vulvar and Vaginal Atrophy Therapy Value Chain Analysis
- 8.1.1 Vulvar and Vaginal Atrophy Therapy Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vulvar and Vaginal Atrophy Therapy Production Mode & Process
- 8.2 Vulvar and Vaginal Atrophy Therapy Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vulvar and Vaginal Atrophy Therapy Distributors
- 8.2.3 Vulvar and Vaginal Atrophy Therapy Customers
9 Global Vulvar and Vaginal Atrophy Therapy Analyzing Market Dynamics
- 9.1 Vulvar and Vaginal Atrophy Therapy Industry Trends
- 9.2 Vulvar and Vaginal Atrophy Therapy Industry Drivers
- 9.3 Vulvar and Vaginal Atrophy Therapy Industry Opportunities and Challenges
- 9.4 Vulvar and Vaginal Atrophy Therapy Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst